218 related articles for article (PubMed ID: 27594744)
1. Chronic Kidney Disease and Lipid Disorders.
Zubovic SV; Kristic S; Prevljak S; Pasic IS
Med Arch; 2016 Jun; 70(3):191-2. PubMed ID: 27594744
[TBL] [Abstract][Full Text] [Related]
2. Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.
Chen H; Chen L; Liu D; Chen DQ; Vaziri ND; Yu XY; Zhang L; Su W; Bai X; Zhao YY
J Proteome Res; 2017 Apr; 16(4):1566-1578. PubMed ID: 28286957
[TBL] [Abstract][Full Text] [Related]
3. Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk.
Dey R; Rajappa M; Parameswaran S; Revathy G
Clin Exp Nephrol; 2015 Dec; 19(6):1054-61. PubMed ID: 25697595
[TBL] [Abstract][Full Text] [Related]
4. Association of dyslipidemia with renal outcomes in chronic kidney disease.
Chen SC; Hung CC; Kuo MC; Lee JJ; Chiu YW; Chang JM; Hwang SJ; Chen HC
PLoS One; 2013; 8(2):e55643. PubMed ID: 23390545
[TBL] [Abstract][Full Text] [Related]
5. Serum C-reactive protein levels in pre-dialysis chronic kidney disease patientsin southern Nigeria.
Adejumo OA; Okaka EI; Okwuonu CG; Iyawe IO; Odujoko OO
Ghana Med J; 2016 Mar; 50(1):31-8. PubMed ID: 27605722
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
[TBL] [Abstract][Full Text] [Related]
7. Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: a prospective study.
Singh RG; Rathore SS; Wani IA; ; Agrawal A; Dubey GP
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):61-6. PubMed ID: 25579717
[TBL] [Abstract][Full Text] [Related]
8. Lipid profile in pre-dialysis chronic kidney disease patients in southern Nigeria.
Adejumo OA; Okaka EI; Ojogwu LI
Ghana Med J; 2016 Mar; 50(1):44-9. PubMed ID: 27605724
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
[TBL] [Abstract][Full Text] [Related]
10. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients.
Khatiwada S; Rajendra KC; Gautam S; Lamsal M; Baral N
BMC Endocr Disord; 2015 Oct; 15():65. PubMed ID: 26510920
[TBL] [Abstract][Full Text] [Related]
11. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in patients with chronic kidney disease.
Hager MR; Narla AD; Tannock LR
Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
[TBL] [Abstract][Full Text] [Related]
13. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
Khurana M; Silverstein DM
Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
[TBL] [Abstract][Full Text] [Related]
14. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
Kon V; Yang H; Fazio S
Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
16. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
17. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
18. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
19. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and chronic kidney disease.
Belarbia A; Nouira S; Sahtout W; Guedri Y; Achour A
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):931-40. PubMed ID: 26354564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
